tiprankstipranks
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA

Enanta Pharmaceuticals Stock Analysis & Ratings

ENTA Stock Chart & Stats

Day’s Range$47.44 - $50
52-Week Range$40.37 - $102.00
Previous Close$48.77
Volume296.54K
Average Volume (3M)218.88K
Market Cap$1.02B
P/E Ratio-8.9
Beta0.64
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-5.52


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ENTA FAQ

What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $40.37 and its highest was $102.00 in the past 12 months.
    What is Enanta Pharmaceuticals’s market cap?
    Enanta Pharmaceuticals’s market cap is $1.02B.
      What is Enanta Pharmaceuticals’s price target?
      The average price target for Enanta Pharmaceuticals is $80.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $130.00 ,the lowest forecast is $35.00. The average price target represents 63.17% Increase from the current price of $49.03.
        What do analysts say about Enanta Pharmaceuticals?
        Enanta Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
          When is Enanta Pharmaceuticals’s upcoming earnings report date?
          Enanta Pharmaceuticals’s upcoming earnings report date is Aug 09, 2022 which is in 83 days.
            How were Enanta Pharmaceuticals’s earnings last quarter?
            Enanta Pharmaceuticals released its earnings results on May 09, 2022. The company reported -$1.63 earnings per share for the quarter, missing the consensus estimate of -$1.424 by -$0.206.
              Is Enanta Pharmaceuticals overvalued?
              According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
                Does Enanta Pharmaceuticals pay dividends?
                Enanta Pharmaceuticals does not currently pay dividends.
                What is Enanta Pharmaceuticals’s EPS estimate?
                Enanta Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Enanta Pharmaceuticals have?
                Enanta Pharmaceuticals has 20,710,000 shares outstanding.
                  What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
                  Enanta Pharmaceuticals reported an EPS of -$1.63 in its last earnings report, missing expectations of -$1.424. Following the earnings report the stock price went up 6.518%.
                    Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
                    Among the largest hedge funds holding Enanta Pharmaceuticals’s share is Farallon Capital Management, L.L.C.. It holds Enanta Pharmaceuticals’s shares valued at 110M.

                      ---

                      Enanta Pharmaceuticals Stock Analysis

                      The Enanta Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Enanta Pharmaceuticals

                      Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      AbbVie
                      Enzon Pharmaceuticals
                      Intercept Pharma
                      Merck & Company

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis